Artificial intelligence in medicine and science

Conversational diagnostic artificial intelligence in ambulatory primary care: a prospective feasibility study

Background​

Artificial intelligence (AI)-based systems show promise for assisting primary care providers (PCPs) with patient care. We aimed to evaluate the safety and quality of clinical conversations of a patient-facing conversational AI system, which engaged in real-world urgent primary care appointments.

Methods​

In this prospective, single-centre, single-arm feasibility study, English-speaking patients aged at least 18 years interacted with the Articulate Medical Intelligence Explorer (AMIE) up to 5 days before a single-complaint urgent primary care appointment. Physician safety supervisors monitored all interactions and were trained to intervene on the basis of predefined safety criteria. AMIE transcripts and summaries were shared with PCPs before the visit. Primary outcomes were the number of supervised conversation safety stops, AMIE's conversation quality assessed by clinical evaluators, and patient and PCP experiences per surveys. This study is registered with ClinicalTrials.gov (NCT06911398).

Findings​

From April to November, 2025, 114 patients were enrolled with 98 completing both the AMIE interaction and the PCP appointment. Zero conversation safety stops were required on the basis of prespecified criteria. Safety supervisors noted one hallucination and added clinical information in five interactions. AMIE's conversations were rated favourably in 87–100% of cases (17 criteria) by clinical evaluators, and 48–96% (16 criteria) by patients. Patient attitudes towards AI improved after interacting with AMIE and remained elevated after the patient's visit with their physician. PCPs completed post-surveys in 60 of 98 cases, including 44 cases in which they reviewed the AMIE transcript before the visit. PCPs found AMIE helpful for visit preparation in 33 of 44 cases and reported that it might have changed their behaviour in 25 of 44 cases.

Interpretation​

Although further research is needed, this study shows the initial feasibility of conversational AI in a real-world setting—assessed via conversation safety and quality, as well as user acceptance—and represents a crucial step towards clinical translation.
 
Having what is in effect your own personal physician available 24/7 might reduce delayed diagnoses (and therefore treatment or prevention advice). How many people notice possible medical problems, but put off seeing a doctor because of cost and inconvenience or embarrassment or fear of being thought of as a hypochondriac? I can think of several times when I should have gone to my GP much earlier, but didn't.
 
Having what is in effect your own personal physician available 24/7
Think bigger: having an entire world-class hospital of physicians, all the specialties, all the sub-specialties, all of which are organized in an orchestra of verification and reasoning with the goal of solving the same problems. The best physician in the world, if that's a thing that can be rated, is nothing compared to that, even available 24/7. Medical AIs will have millennia of clinical and research experience on second one.
 
Think bigger: having an entire world-class hospital of physicians, all the specialties, all the sub-specialties, all of which are organized in an orchestra of verification and reasoning with the goal of solving the same problems. The best physician in the world, if that's a thing that can be rated, is nothing compared to that, even available 24/7. Medical AIs will have millennia of clinical and research experience on second one.
Do you work for OpenAI et al? :laugh: You don't seem to apply your usual skepticism for all things me/cfs to machine learning tech.
 
Glass AI--AI that generates differential diagnosis and clinical plans

Recently I learned about this AI tool, which is currently available for anyone to use without cost or registration.

Edit: Darn I forgot the link: https://glass.health/ai

I'm playing around with it to see how well it understand ME/CFS. It seems like it's familiar with it. Here's the DDx it generates for one case I made up:
I don't think this is a meaningful test, if you feed the AI the clinical language directly related to me/cfs. My language has evolved considerably from pre to post diagnosis, and I still struggle to explain it to others.
 
Think bigger: having an entire world-class hospital of physicians, all the specialties, all the sub-specialties, all of which are organized in an orchestra of verification and reasoning with the goal of solving the same problems.
Yes, but you wouldn't interface directly with the sub-specialist. The AI GP would bring those others in when necessary.

We are so far avoiding paying full cost of AI service. It sounds like AI companies still in the "milk investors using wild promises" phase. Learning to be the friendly GP for an individual requires a different set of resources than diagnosing complex diseases, and with different size of requests, so referrals seem logical.

Hopefully the "gouge the customers to the max" phase will be short, and replaced by a completely different economic system.
 
We are so far avoiding paying full cost of AI service. It sounds like AI companies still in the "milk investors using wild promises" phase.
It's more that the initial costs are very high, but keep going down. Something like 50% per quarter over the last 4 years, or something like it. What you can do with $100 of a top-end model, at full cost, will be a lot cheaper and better in 6 months, then the same after that. And we don't even have ASICs yet, where parts of the models are baked in the chips.

The hardware industry saw similar scaling, although working purely with software adds a whole other layer of optimization. A current smartphone has more computing power than all the world's computers at some point in the past, probably around the late 70s.

Exponentials are wild, it's very hard to wrap your head around them, but so far nothing I've seen out of AI has surprised me. This stuff just works.
 
It's just hard to understand how information sciences scale
So this is the thing that I think is far more likely than some superhuman intelligence. It’s human level intelligence or rather knowledge work as a commodity. The industrial revolution did allow advances but the main factors were the repetition and scale of what humans could already do. Then came the advances of precision engineering and manufacturing. Map that to knowledge work and you have a world changing technology but not the silicon valley vision of a digital god. And one which doesn’t necessarily have the moats some see either.

It’s part of why I don’t see the economics of this adding up though. The labs and big companies cannot carry on doing what they doing forever. It’s burning money.
 
So this is the thing that I think is far more likely than some superhuman intelligence. It’s human level intelligence or rather knowledge work as a commodity...Map that to knowledge work and you have a world changing technology but not the silicon valley vision of a digital god.
I see no reason to postulate either of these things when there's an infinite range of possibilities in between them. It doesn't seem to work like a human and there's no reason to think of it as what people would typically think of a god. Things are allowed to be different. And I believe it's clear that it is doing things humans couldn't already do.
It’s part of why I don’t see the economics of this adding up though. The labs and big companies cannot carry on doing what they doing forever. It’s burning money.
It doesn't have to and they don't have to. Probably within a year a five year old will be able to download some weights and do things most humans didn't think were ever possible. Where will that leave those that used to do those things for a living? Do those economies still make sense? I think not, something new will be necessary and the hope is that this should be beneficial to all, but the outcome seems less clear.
 
Thanks to everyone for your replies. A family member is in the hospital and the available time at the moment is minimal. I will post to another thread a proposed hypothesis which was identified via AI but -to the best of my knowledge- has a biological basis worth to be considered.
 
An interesting paper with more work from the Baker lab using AI to help design proteins

De novo design of cysteine proteases

Choi, Hojae; Bauer, Magnus S.; Coventry, Brian; Venkatesh, Preetham; Chen, Anqi; Kim, Donghyo; Bera, Asim K.; Kang, Alex; Nguyen, Hannah; Sadre, Shayan; Decarreau, Justin; Joyce, Emily; Shankaran, Bhanumathi; Thompson, Tuscan Rock; Greenstein, Gabriel; Didi, Kieran; Schaaf, Lars L.; Gershon, Jacob Merle; Shida, Alexander F.; Lee, Gyu Rie; Hilvert, Donald; Pellock, Samuel J.; Baker, David

Abstract
Despite advances in de novo enzyme design, success has been largely limited to low-energy-barrier model reactions. Amide bonds such as those linking amino acids along the peptide backbone are stable for hundreds of years in neutral aqueous solution because of the high energy barrier to hydrolysis.

Here we describe the de novo design of enzymes that use an activated cysteine nucleophile to hydrolyse the polypeptide backbone in a sequence-dependent manner, with a success rate of 13/69 = 19% and rate enhancements over the background reaction (kcat/kuncat) of up to 3 × 107. The designed proteases have folds that are very different from proteases in nature (TM score < 0.50), and six crystal structures are very close to the design models (Cα root mean squared deviation of <1.2 Å), highlighting the capacity for generalization and the accuracy of the design methodology.

Experimental and computational analyses suggest that the remaining gap in activity to the most active native cysteine proteases arises from imperfections in active-site preorganization and substrate positioning. The designed proteases efficiently cleave their targets in mammalian cells, opening the door to a wide range of synthetic biology applications.

Web | DOI | PDF | Nature

Also see the discussion here on Ars.

A protein is a chain of amino acids held together by what are called peptide bonds. On their own, those bonds are extremely stable; they’re estimated to have a half-life of several hundred years. But in Earth’s environment, most proteins don’t last nearly that long. That’s because organisms have evolved a handful of ways to catalyze the break-up of peptide bonds, which have diversified into countless specialized protein-digesting enzymes. Proteases are everywhere and generally make short work of any proteins that find their way into the environment.

Now, researchers have basically short-circuited the diversification process, using AI-based protein design tools to take the catalytic core of two types of protease and replace the entire rest of the protein. The resulting enzymes could be tuned to cut specific proteins in half, and the researchers demonstrated their effectiveness by using them to cut proteins associated with neurological diseases


The potential therapeutic use of this is complicated. Proteins are often difficult to deliver to the site where they’re needed, and can often trigger an immune response. Things get even more challenging if the protease target is inside a cell rather than on the exterior. That would likely require the target cells to make the protease, which would involve delivering the gene encoding it to the cells where it’s needed. So, there are considerable hurdles that would need to be cleared before we could potentially start developing therapies using this technology.
The researchers also highlight how the work shows some limitations of the tools. As used, they successfully designed proteins that matched all the physical constraints they were given: They folded up into structures that brought the amino acids needed to catalyze a reaction into roughly the right location, and latched on to specific target amino acid sequences.

But we don’t, at the moment, have the ability to tell these tools we want any specific catalytic activity
 
Back
Top Bottom